Apr 22 2010
KARO BIO'S (STO:KARO) PROJECTS ARE PROGRESSING
• Net sales for the period amounted to MSEK - (2.2)
• Net loss for the period amounted to MSEK 40.5 (45.9)
• Loss per share amounted to SEK 0.26 (0.36)
• Cash flow from operating activities for the period amounted to MSEK -43.0 (-41.0). Cash, cash equivalents and other short-term investments totaled MSEK 192.7 (200.4) at the end of the period
• On March 11, The New England Journal of Medicine published clinical phase II results on eprotirome and its ability to further reduce serum LDL cholesterol levels in statin-treated patients
• Fredrik Lindgren was appointed new President and CEO of Karo Bio and will on April 23 succeed Per Olof Wallström, who has resigned after five years with the company